Literature DB >> 15355911

Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays.

Colette Charpin1, Jean-Philippe Dales, Stéphane Garcia, Séverine Carpentier, Amina Djemli, Lucile Andrac, Marie-Noëlle Lavaut, Claude Allasia, Pascal Bonnier.   

Abstract

PURPOSE: The aim of the study was to evaluate CD31 and CD105 immunohistochemical expressions in tissue microarrays from 360 breast carcinomas. STUDY
DESIGN: Computerized (ACIS/Chromavision) assisted image analysis was performed to compare immunoreactions in tissue microarrays with those in current paraffin and frozen sections. We also aimed to determine the CD105 and CD31 prognostic significance and relevance in routine practice by correlating results of immunodetections with patients' (n = 360) outcome (14.3-year follow-up).
RESULTS: The results show (a) that in tissue microarrays, the CD31 and CD105 expression quantified by image analysis device did not correlate with the measurements assessed on routine paraffin sections; (b) that CD105 expression is endowed of a prognostic significance in paraffin sections in terms of overall survival (P < 0.01), whereas in contrast, CD31 on paraffin sections did not correlate with patients overall survival; (c) that semiquantitative analysis of CD105 expression correlated with the image analysis measurements in frozen sections (rho = 0.671, P < 0.01) and paraffin (rho = 0.824, P < 0.01) sections. However, paraffin sections were less immunostained than frozen ones.
CONCLUSIONS: It is concluded (a) that CD105 may be suitable in paraffin sections to evaluated neoangiogenesis; and (b) that tissue microarrays are not suitable substrates for neoangiogenesis evaluation as a prognostic indicator in breast carcinomas, in contrast to current tissue sections.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15355911     DOI: 10.1158/1078-0432.CCR-04-0021

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

Review 1.  Endoglin-targeted cancer therapy.

Authors:  Ben K Seon; Akinao Haba; Fumihiko Matsuno; Norihiko Takahashi; Masanori Tsujie; Xinwei She; Naoko Harada; Shima Uneda; Tomoko Tsujie; Hirofumi Toi; Hilda Tsai; Yuro Haruta
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

2.  Study of angiogenesis in invasive breast carcinoma by morphometry and immunohistochemistry.

Authors:  J K Bhatia; Tripta Chaudhary; Dibyajyoti Boruah; Reena Bharadwaj
Journal:  Med J Armed Forces India       Date:  2021-12-16

3.  Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature.

Authors:  Shima Uneda; Hirofumi Toi; Tomoko Tsujie; Masanori Tsujie; Naoko Harada; Hilda Tsai; Ben K Seon
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

4.  Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma.

Authors:  Alexander S Parker; Christine M Lohse; Bradley C Leibovich; John C Cheville; Yuri M Sheinin; Eugene D Kwon
Journal:  Hum Pathol       Date:  2008-06-05       Impact factor: 3.466

5.  Down-regulation of GRIM-19 expression is associated with hyperactivation of STAT3-induced gene expression and tumor growth in human cervical cancers.

Authors:  Ying Zhou; Min Li; Ying Wei; Dingqing Feng; Cheng Peng; Haiyan Weng; Yang Ma; Liang Bao; Shreeram Nallar; Sudhakar Kalakonda; Weihua Xiao; Dhananjaya V Kalvakolanu; Bin Ling
Journal:  J Interferon Cytokine Res       Date:  2009-10       Impact factor: 2.607

6.  Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.

Authors:  Masanori Tsujie; Tomoko Tsujie; Hirofumi Toi; Shima Uneda; Ken Shiozaki; Hilda Tsai; Ben K Seon
Journal:  Int J Cancer       Date:  2008-05-15       Impact factor: 7.396

7.  Columnar cell lesions and pseudoangiomatous hyperplasia like stroma: is there an epithelial-stromal interaction?

Authors:  Rosemary A Recavarren; Mamatha Chivukula; Gloria Carter; David J Dabbs
Journal:  Int J Clin Exp Pathol       Date:  2009-10-10

8.  c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays.

Authors:  S Garcia; J-P Dalès; J Jacquemier; E Charafe-Jauffret; D Birnbaum; L Andrac-Meyer; M-N Lavaut; C Allasia; S Carpentier-Meunier; P Bonnier; C Charpin-Taranger
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

9.  Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome.

Authors:  C Charpin; S Giusiano; S Charfi; V Secq; S Carpentier; L Andrac; M-N Lavaut; C Allasia; P Bonnier; S Garcia
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

10.  Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination.

Authors:  Charlotte Anderberg; Sara I Cunha; Zhenhua Zhai; Eliane Cortez; Evangelia Pardali; Jill R Johnson; Marcela Franco; Marta Páez-Ribes; Ross Cordiner; Jonas Fuxe; Bengt R Johansson; Marie-José Goumans; Oriol Casanovas; Peter ten Dijke; Helen M Arthur; Kristian Pietras
Journal:  J Exp Med       Date:  2013-02-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.